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Retinoid acid is a metabolite of vitamin A and functions as an important factor in cell survival, differentiation and death. Most 
previous studies on retinoid metabolism have focused on its association with cancer, hematologic and dermatologic disorders. 
Given the special concern over the recent increase in the prevalence of diabetes worldwide, the role of retinoid metabolism on 
glucose metabolism and insulin resistance in the human body is of marked importance. Therefore, in this issue, we review the 
literature on the association of retinoid metabolism with glucose tolerance, with regard to insulin secretion, pancreatic autoim-
munity, insulin sensitivity and lipid metabolism. Further, we tried to assess the possibility of using retinoids as a novel therapeu-
tic strategy for diabetes. 
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INTRODUCTION
Diabetes mellitus is one of the many chronic diseases that has 
a markedly increasing rate of prevalence. In Korea, the preva-
lence of diabetes reached almost 10% in 2009 in subjects older 
than 20 years of age [1]. Type 1 diabetes is an autoimmune dis-
order characterized by the destruction of pancreatic islets by 
immunologic insult and type 2 diabetes is caused by insulin 
resistance and decompensated insulin secretion from pancre-
atic islets. As these two main types of diabetes are increasing 
worldwide, vitamins have gained particular attention as envi-
ronmental “agents of influence.”
  Vitamin A is an essential vitamin that must be derived from 
vitamin-A-rich foods as well as foods containing the carotenoid 
β-carotene, which is composed of 2 retinol molecules [2]. Ret-
inoic acid (RA) is the active metabolite of vitamin A, and is a 
critical signaling molecule during the development of verte-
brates [3]. Retinoids have long been appreciated as a crucial 
factor for controlling the differentiation program of certain 
epithelial cells and for their effects on vision, growth, reproduc-
tion and resistance to infection. Vitamin A deficiency could re-
sult in impaired cellular differentiation, reduced resistance to 
infection, anemia and ultimately, death. In a very old study by 
Wolbach and Howe [4] in 1925, when the rats were deprived 
of vitamin A from diet, epithelial growth was greatly augment-
ed and they could see neoplasm-like growth in epithelial tis-
sues. Conversely, many aquatic species (such as shark) exhibit 
a paucity of neoplasms because of their high content of vita-
min A [5]. Currently, retinoic acid is officially accepted as the 
primary treatment for acute promyelocytic leukemia [6].
  Although many studies are performed on the relationships 
between retinoic acid metabolism and embryogenesis and 
cancer, not many studies have looked at the relationship be-
tween retinoic acid and diabetes. Therefore, we want to briefly 
review the recent research in retinoic acid metabolism and its 
relationships with diabetes from the clinical and scientific per-
spectives.
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OVERVIEW OF RETINOIC ACID 
METABOLISM
Analogs of retinol, with or without biological activity, are called 
retinoids. The only source of retinoids for most animals is diet 
as these compounds cannot be synthesized de novo. Diet (for 
example through milk, liver, and eggs) provides retinol as reti-
nyl ester or a provitamin carotenoid (for example, in carrots 
and red pepper), of which β-carotene represents the most effi-
cient precursor [2]. The predominant natural retinoid in cir-
culation is retinol in micromolar levels, which is derived from 
the carotenoid, β-carotene or provitamin A, and retinyl ester, 
particularly palmitate, is the most abundant storage form, with 
liver serving as the main, but not the sole site of storage. The 
primary function of retinol and retinyl is to serve as the pre-
cursor for the biosynthesis of active retinoids, that is, the first 
initiator. Retinol has 6 biologically active isoforms: all-trans, 
11-cis, 13-cis, 9,13-di-cis, 9-cis, and 11,13-di-cis, with all-trans 
being the predominant form (Fig. 1). 
  All-trans RA (atRA) is a small lipophilic molecule (300 dal-
tons) that circulates in plasma and is bound to albumin at a 
concentration of 1 to 10 nmol/L [7,8]. Two retinoic acid (RA) 
isomers have been identified in vivo: 9-cis RA and 13-cis RA. 
The physiological function of 13-cis RA is unclear and it is de-
tected at significantly lower concentrations in both mice and 
humans [9,10]. 9-cis RA binds with high affinity to a distinct 
type of retinoic receptor, the retinoid X receptor (RXR) [11,12]. 
AtRA is generated from the parental vitamin A molecule, all-
trans-retinol, by two consecutive oxidation steps: oxidation 
from retinoid to retinal and then to RA (Fig. 2). These oxida-
tion steps are mediated by retinol dehydrogenases and retinal-
dehyde dehydrogenases. Two classes of enzymes function as 
retinol dehydrogenases in vitro: medium-chain alcohol dehy-
drogenases and short-chain dehydrogenases/reductases (SDRs) 
[13]. AtRA and 9-cis-RA can regulate the expression of multi-
ple genes [12], and as the transcriptional activities of RA can 
lead to differentiation, cell cycle arrest, and apoptosis, the 
compound often inhibits cell growth. Such activities enable 
RA to suppress carcinoma cell proliferation and provide the 
rationale for use in cancer treatment. RA is clinically used for 
treatment of malignancies (e.g., promyelocytic leukemia, Ka-
posi’s sarcoma, and premalignancies) [14]. 
  The transcriptional activities of RAs are mediated by several 
nuclear receptors (Fig. 2). Retinoic acid receptor (RAR) belongs 
to a large family of steroid hormone nuclear receptors and 
RARs α, β, and γ bind both atRA and 9-cis RA, whereas the 
RXRα, β, and γ bind to 9-cis RA. 13-cis RA is not a ligand for 
retinoid receptors, but can readily convert to retinoid receptor 
ligand. The mRNA expression of RARα, RXRα, and RXRβ is 
ubiquitous, whereas RARβ, γ, and RXRγ exhibit tissue-re-
stricted patterns of expression [15,16]. RXRs regulate tran-
scription as homodimers, and they also serve as obligatory 
heterodimerization partners for multiple other nuclear recep-
tors within subclass I of the family, including RARs, peroxi-
some proliferator-activated receptors (PPARs), and the vita-
min D receptor, thyroid hormone receptors and farnesoid X 
receptor, liver X receptor, and other key transcriptional sen-
sors of nutrients and metabolites that help maintain homeo-
stasis in metabolism and immune responses [17,18]. 
  The transcriptional activation by RAR is dependent on the 
formation of the RAR/RXR heterodimer, which occurs on two 
interfaces, the ligand-binding domain (LBD) and DNA-bind-
ing domain (DBD). Mice null for RARα show some of the fea-
tures of vitamin A deficiency with decreased viability, growth 
deficiency, and male sterility [19]. However, most of the defects 
of these mice could be reversed by RA treatment. Null mice 
for RARβ exhibit a selective loss of striosomal compartmen-
talization in the rostral striatum and also display locomotor 
defects, which are correlated with dopamine signaling, impli-
cating retinoids in the regulation of brain function [20,21].  Fig. 1. The chemical structures of retinoids.
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RARγ is highly expressed in the skin and RARγ-null mice dis-
play some defects associated with vitamin A deficiency, which 
can be rescued by RA treatment, indicating that RARγ medi-
ates some of the retinoid functions in vivo [22,23]. 
  Retinol is delivered to target tissue by the ligand-bound cel-
lular retinol binding protein (CRBP) (Fig. 2), where retinol is 
degraded to produce retinoids through multiple enzymatic re-
actions [3]. In 1970, the cell surface receptor for retinol bind-
ing protein (RBP) was identified and since then, there has been 
accumulating evidence of the existence of the RBP receptor in 
various tissues [24]. This cell surface receptor binds to RBP 
and mediates retinol uptake from the ligand-bound CRBP. 
This cell surface receptor for RBP was shown to be stimulated 
by retinoic acid gene 6 (STRA6). STRA6 is a widely expressed 
multitransmembrane protein that is broadly expressed in mu-
rine embryo, but has more restricted expression in adults. 
  In target tissue, retinol either associates with CRBP or serves 
as a substrate for several cytosolic and microsomal enzymes 
termed retinol dehydrogenases (RDH) that oxidize retinol to 
retinaldehyde (Rald) [25,26]. Retinol dehydrogenases are 
members of the alcohol dehydrogenase (ADH) or SDR fami-
lies. Retinol metabolism is catalyzed by ubiquitously expressed 
ADH3 as well as by the tissue-restricted ADH1 and ADH4. All 
three isoforms could oxidize all-trans retinol to all-trans reti-
naldehyde. 
  RA is produced from Rald through irreversible oxidation 
by retinaldehyde dehydrogenase (Raldh) (Fig. 2) [27]. It has 
been demonstrated that three distinct isoforms of Raldhs of 
the ALDH1A class exist in vertebrates (ALDH1A1 or Raldh1, 
ALDH1A2 or Raldh2, and ALDH1A3 or Raldh3) and one 
Raldh of ALDH8 class called Raldh4. Rodents have an addi-
tional ALDH1A enzyme called ALDH1A4 in rat and AL-
DH1A7 in mouse [28].
Fig. 2. The retinoid metabolic pathway. CRBP, cellular retinol binding protein; RBP, retinol binding protein; TTR, transthyretin; 
BCO-I, β,β-carotene-15,15′-monooxygenase; BCO-II, β,β-carotene-9′,10′-dioxygenase; CRABP, cellular retinoic acid binding 
protein; ADH, alcohol dehydrogenase; SDR, short-chain dehydrogenases/reductases; Raldh, retinaldehyde dehydrogenase; CYP26, 
cytochrome P450 family 26; HAT, histone acetyltransferase; RXR, retinoid X receptor; RAR, retinoic acid receptor; HDAC, his-
tone deacetylase.  
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RETINOID METABOLISM AND DIABETES-
EVIDENCE FROM HUMAN STUDIES
The association of retinoid metabolism and insulin sensitivity, 
obesity and metabolism has been studied in humans. Basically, 
the results of these studies are inconsistent and it’s difficult to 
draw a conclusion based on previous results. In the study by 
Krempf et al. [29], serum vitamin A level was significantly de-
creased in type 1 diabetes and increased in type 2 diabetes 
compared with non-diabetic controls. In another study, serum 
vitamin A level was decreased in young type 1 diabetes [30]. 
When the vitamin A level was measured in subjects with im-
paired glucose tolerance (IGT) status, serum vitamin A levels 
were higher in IGT subjects compared with normal controls 
[31]. Furthermore, there was a univariate association between 
vitamin A levels and insulin resistance assessed by the homeo-
stasis model assessment index. Another interesting study by 
Erikstrup et al. [32] demonstrated that retinol-binding protein 
(RBP)-to-retinol ratio was elevated in patients with type 2 dia-
betes. From these results, we see that serum vitamin A levels 
are high in the hyperinsulinemic status, such as IGT or type 2 
diabetes, and low in the insulin-depleted status, such as type 1 
diabetes, although more studies are needed to clarify the 
mechanism.
  RXR is crucial in the function of so many other nuclear re-
ceptors, since their heterodimeric partner is RXR. RXR is par-
ticularly important as it is the heterodimeric partner for 
PPAR-γ, a terminal regulator of adipogenesis. As RXR is es-
sential for the function of PPAR-γ, the role and expression of 
RXR in insulin-sensitive tissues might be of interest. In the 
study by Codner et al. [33], all 3 isoforms of RXR, α, β, and γ 
were present in human skeletal muscle extracted through per-
cutaneous biopsy of the vastus lateralis muscle. RXR isoform 
expression is not significantly different between the groups di-
vided by glucose tolerant status and did not show any relation-
ship with the metabolic parameters measured, including insu-
lin, insulin resistance markers or glucose. They concluded that 
RXR isoforms were not tightly regulated by the factors related 
to insulin resistance or diabetes.
  Several genetic studies were performed under the hypothe-
sis that genetic variation in the components in the retinoid 
metabolism pathway might affect glucose metabolism or dia-
betes in humans. Wang et al. [34] screened 10 exons of the 
RXR-γ genes in the offspring of patients with type 2 diabetes, 
and identified 14 single nucleotide polymorphisms (SNPs). 
They analyzed the association of these SNPs with the metabol-
ic parameters and found that none of the variants or haplotypes 
were associated with glucose in this population. Instead, three 
of the four variants detected in the mass screening were asso-
ciated with fasting free fatty acid levels and two variants were 
associated with triglyceride levels. They also found out that 
RXR-γ haplotypes were associated with several measures of 
pancreatic β-cell function. These studies suggest that, although 
RXR-γ SNPs show some association with pancreatic β-cell 
function, it is unlikely that this gene is linked to type 2 diabetes.
  The Diabetes Genome Anatomy Project (DGAP) was initi-
ated to use a multi-dimensional genomic approach to charac-
terize the relevant set of genes and gene products as well as the 
secondary changes in gene expression that occur in response 
to the metabolic abnormalities present in diabetes. In the inte-
grative analysis of the 16 DGAP data sets in multiple tissues, 
conditions, array types, laboratories, species and study designs, 
Park et al. [35] revealed that the gene for retinol saturase (Ret-
Sat) is a widely shared component of mechanisms involved in 
insulin resistance and sensitivity. RetSat is an oxidoreductase 
that catalyzes the reaction of retinol to 13,14-dihydroretinol 
(dhretinol), and is induced during adipocyte differentiation 
[36]. RetSat expression is controlled by PPAR-γ through an in-
tronic PPARγ response element (PPRE) in adipocytes. Abla-
tion of RetSat expression in preadipocytes inhibited adipogen-
esis, whereas ectopic expression of RetSat enhanced differenti-
ation [37]. RetSat-null mice gained weight and the increased 
adiposity of RetSat-null mice was associated with up-regula-
tion of PPAR-γ, a key transcriptional regulator of adipogenesis 
[38]. Based on these results, RetSat appears to be a new candi-
date factor that highlights the importance of the retinol path-
way in diabetes, adipogenesis, and insulin resistance.
RXR-PPAR-γ HETERODIMER: TARGETS IN 
METABOLIC DISEASES
The RXRs play unique and modulatory roles in multiple path-
ways in the body since they are expressed in various tissues of 
the body and they form multiple forms of heterodimers with a 
large number of other nuclear receptors. There are two types 
of nuclear receptor heterodimers, that is, “permissive” and 
“non-permissive” heterodimers. Permissive heterodimers (for 
example, PPARs, LXRs) can be indistinctly activated by ligands 
of RXR or its partner receptor and are synergistically activated 
in the presence of both ligands [39]. In non-permissive het-171
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erodimers (for example, thyroid receptors, vitamin D recep-
tors), the ligand-induced transcriptional activities of RXR are 
suppressed. Thus, in these complexes, RXR is a “silent partner.” 
For permissive heterodimers, RXR agonist can demonstrate 
pharmacological activities that reflect activation of these part-
ners. 
  Although rexinoids and PPAR-γ agonists produce insulin 
sensitization in rodent models of type 2 diabetes, the two com-
pounds produce differential tissue-specific gene regulation. 
Using the Zucker diabetic fatty rat as a model, Singh Ahuja et 
al. [40] compared the effects of a PPAR-γ agonist, rosiglitazone, 
and a Rexinoid, the RXR-specific ligand (LG268) on metabolic 
gene expression in white adipose tissue, skeletal muscle and 
liver. They showed that rosiglitazone decreased the mRNA ex-
pression of tumor necrosis factor-alpha (TNF-α) and increased 
the mRNA expression for glucose transporter 4 (GLUT4), pal-
mitoyl-transferase (MCPT), stearoyl CoA desaturase (SCD1), 
and fatty acid translocase (CD36) in white adipose tissue. In 
contrast, LG268 increased TNF-α mRNA and had no effect, 
or suppressed the mRNA levels of GLUT4, MCPT, SCD1, and 
CD36. However, these two compounds showed differential ef-
fects in mRNA levels of the genes in liver compared with that 
of adipose tissue, suggesting the antidiabetic effects of RXR 
agonists are not just a reflection of RXR-PPAR-γ activation, 
but may act through complicated pathways.
  Treatment of diabetic (db/db) mice with either LG268 or 
rosiglitazone significantly increased insulin-stimulated glucose 
transport in skeletal muscle [41]. LG268 increased insulin-
stimulated insulin receptor substrate (IRS)-1 tyrosine phos-
phorylation and Akt phosphorylation in muscle. In contrast, 
rosiglitazone increased adenylyl cyclase-associated protein 
gene expression and insulin-stimulated SH3-domain kinase 
binding protein 1 (SH3KBP1) phosphorylation without affect-
ing the IRS1/Akt pathway. Another study by Li et al. [42] 
showed similar results when Zucker diabetic rats were treated 
with AGN194204, an RXR agonist or troglitazone, a PPARγ 
agonist. These data also suggest that rexinoid and rosiglitazone 
produce insulin sensitization in skeletal muscle via distinct 
pathways. 
  In contrast, studies using antagonists for PPAR-γ and RXR 
showed different results. In the study by Yamauchi et al. [43], 
they investigated the phenotype resulting from functional an-
tagonism of PPARγ/RXR, using a PPARγ antagonist and a RXR 
antagonist in mouse models. Moderately decreased RXR/
PPARγ activity in wild-type mice treated with PPARγ antago-
nist and RXR antagonist showed decreased triglyceride (TG) 
content in white adipose tissue (WAT), skeletal muscle, and 
liver. The antagonists also potentiated the effect of leptin and 
increased fatty acid combustion and energy dissipation, there-
by ameliorating-induced obesity and insulin resistance. Para-
doxically, when the RXR/PPARγ activity was decreased mark-
edly by treatment of heterozygous PPAR-γ-deficient mice with 
an RXR antagonist or a PPARγ antagonist, there was depletion 
of WAT, marked decrease in leptin levels and energy dissipa-
tion, and increased TG content in skeletal muscle and liver, 
thereby leading to the re-emergence of insulin resistance. These 
data suggest that appropriate functional antagonism of PPARγ/
RXR may be a logical approach to protect against obesity and 
related diseases such as type 2 diabetes.
  The most striking differences between rexinoids and PPARγ 
agonists are their influence on body mass gain and food con-
sumption. The thiazolidinediones (TZDs) are known to pro-
duce increased body weight and fat mass. Rexinoids reduce 
food consumption, body mass gain and fat mass in insulin-re-
sistant or diabetic rodents [44,45]. Another difference between 
rexinoid and TZDs are the effects on TG levels and lipoprotein 
lipase (LPL) activity. TZDs have been shown to decrease cir-
culating TG levels and to increase LPL activity. Rexinoids in-
crease TG and decrease LPL activity in heart and skeletal mus-
cle [46].
RETINOID METABOLISM AND INSULIN 
SECRETION
Pancreatic β-cell dysfunction is one of the most important 
pathogenic mechanisms in the development of type 2 diabe-
tes, and the most important pathogenic mechanism in type 1 
diabetes. Type 2 diabetes develops when the insulin secretory 
function in pancreatic islets cannot compensate for the hyper-
insulinemia that develops due to insulin resistance. 
  AtRA induces pancreas development and differentiation 
into acini, but restricting dietary vitamin A in diabetic-prone 
rats reduces diabetes and insulitis, suggesting the important 
role of atRA in the development of pancreas islets and in the 
prevention of pancreatic dysfunction [47-49]. It is evident that 
RA affects the function of pancreatic β-cells: 1) it restores in-
sulin secretion in vitamin-deficient rats [50], 2) it induces both 
1st and 2nd phase insulin secretory responses to glucose in ex-
plants of human fetal pancreas [51], 3) it increases insulin pro-
duction in insulin-secreting cell lines [52], and 4) retinoid acid 172
Rhee E-J, et al.
Diabetes Metab J 2012;36:167-180 http://e-dmj.org
increases pancreatic glucokinase activity and mRNA levels in 
the insulinoma cell line and primary rat pancreatic islets [52]. 
Using the insulin-producing cell line, INS-1, Blumentrath et al. 
[53] revealed that RAR and RXR were present in INS-1 cells 
and that 9cRA and atRA inhibited the proliferation of INS-1 
cells. They also showed that a moderate concentration (100 nM) 
of atRA and 9cRA increased glucose-stimulated insulin release 
in these cells in parallel with GLUT2 expression. 
  The significant difference that 9cRA has over atRA is that 
9cRA is the only ligand for RXR, which serves as an obligatory 
partner for RAR and numerous other NRs that regulate me-
tabolism and energy balance. Applying a liquid chromatogra-
phy/tandem mass spectrometry assay, Kane et al. [54] detected 
not only atRA, but also 9cRA in the mouse pancreas. They 
showed that 9cRA decreases with feeding and after glucose 
dosing and varies inversely with serum insulin. 9cRA reduces 
glucose-stimulated insulin secretion in mouse islets by reduc-
ing GLUT2 and glucokinase activity. 9cRA also reduces Pdx-1 
and HNF5α mRNA expression. Pancreatic β-cells generate 
9cRA, and mouse models of reduced β-cell number or diabe-
tes have reduced 9cRA, in contrast with abnormally high ex-
pression of 9cRA in mice with diet-induced obesity and β-cell 
hyperplasia, suggesting 9cRA is a pancreatic-specific autacoid 
with multiple mechanisms of action in pancreatic insulin se-
cretion. In contrast, Chertow et al. [55] reported that 9cRA 
stimulates insulin secretion from the same cell line, possibly 
through RXR in the same cell line, and they suggested that 
these effects are greater than that observed with atRA, oppos-
ing the results from the previously mentioned group.
  A very recent study suggested that a new member in the 
retinoid metabolic pathway might be involved in pancreatic 
insulin secretory function. Karasawa et al. [56] reported that 
the pancreatic islet isolated from HFD-fed BDF1 mice showed 
a reduced insulin content and glucose-induced insulin secre-
tion from these islets was also significantly impaired with si-
multaneous increases in glucagon-positive cells, suggesting 
the expansion of pancreatic α-cells. In the comprehensive gene 
expression analysis of the pancreatic islets of HFD-fed BDF1 
mice and spontaneously diabetic C57BL/KsJ
db/db mice, retinal-
dehyde dehydrogenase 3 (Raldh3) expression was significantly 
increased [57]. Exposure to higher glucose concentration sig-
nificantly increased Raldh3 expression in murine β and α cell 
lines, and overexpression of Raldh3 reduced insulin secretion 
in β-cells and increased glucagon secretion in α-cell lines. 
Furthermore, knockdown of Raldh3 expression decreased the 
glucagon secretion in α-cell line. Given that Raldh3 catalyzes 
the conversion of 13-cis-retinaldehyde to 13-cis-RA, they also 
revealed that 13-cis RA significantly reduces cell viability in 
insulin-secreting cell and α-cell lines. These results suggest 
that Raldh3 might be a novel factor that regulates the balanced 
mechanisms of insulin and glucagon secretion in the pancre-
atic islets.
  There are studies showing the effect of RXR activation on 
pancreatic insulin secretory function [58]. In spontaneously 
diabetic C57BL/KsJ
db/db mouse models, both RXR agonist and 
PPARγ agonists, when given for 14 weeks, showed significant 
hypoglycemic effects and the insulin content in islets from 
both groups showed significant increases compared with con-
trols, suggesting the equal effectiveness of the two agents on 
increasing pancreatic insulin content. 
EFFECTS OF RETINOID ON THE 
PREVENTION OF TYPE 1 DIABETES 
THROUGH THE MODULATION OF IMMUNE 
FUNCTION
 
Type 1 diabetes is an autoimmune disorder with numerous 
genetic susceptibility loci, including major histocompatibility 
complex (MHC) and a much larger list of immunomodulatory 
environmental factors that have a negative or positive influ-
ence on pancreatic β-cells [59]. Vitamin A is considered to be 
one of the “immunomodulatory” factors that affects the pro-
gression of type 1 diabetes, and it is known to be deficient in 
type 1 diabetes patients [60]. There have been several studies 
on the beneficial effects of retinoids on the modulation of im-
mune function in the development of type 1 diabetes in ani-
mal models.
  In the study by Van et al. [61], they used two ways to prove 
that retinoid affects the development of type 1 diabetes in a 
specific mouse model. When the splenocytes from newly dia-
betic non-obese diabetic (NOD) mice were adoptively trans-
ferred to NOD/SCID recipient mice, the control recipient mice 
developed diabetes within 3 weeks. However, atRA treatment 
not only significantly delayed the onset of diabetes for 5 weeks, 
but also significantly reduced diabetes incidence compared 
with controls. Histological studies showed that while pancreas 
from recipient mice showed severe destructive insulitis, either 
intact islets or stationary peri-insulitis were observed in atRA-
treated mice. These results were due to the fact that atRA treat-
ment induced T regulatory (Treg) cell-dependent immune tol-173
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erance by suppressing both CD4+ and CD8+ T effector cells, 
while promoting Treg cell expansion. These results demon-
strate that atRA treatment has immunomodulatory effects on 
the prevention of type 1 diabetes through the effects on Treg 
and Teff cells.
  Another study examined the effects of the synthetic vitamin 
A derivative, etretinate and atRA in three preclinical models of 
type 1 diabetes, spontaneous and cyclophosphamide (CY)-ac-
celerated diabetes in NOD mice, and diabetes induced in a 
susceptible rodent strain by multiple low doses of streptozoto-
cin (MLD-STZ) [62]. When etretinate and atRA were admin-
istered prophylactically to MLD-STZ mice, both drugs effec-
tively prevented clinical signs of diabetes with reduced emer-
gence of autoreactive CD4+ CD25+ T cells, but not with the 
emergence of Foxp3+ Treg in the peripheral compartment. In 
spontaneously diabetogenic NOD mice, atRA prophylaxis 
markedly reduced hyperglycemia and incidence of diabetes. 
However, in the CY-NOD mice, in which the proportion and 
function of CD4+ Foxp3+ Treg cells were abrogated with cy-
clophosphamide, atRA failed to show protective effects on 
type 1 diabetes, suggesting the that effectiveness of T1DM 
suppression by retinoids depends on the presence of Tregs, 
which down-modulate immunoinflammatory events.
  These results indicate that atRA exerts a protective effect on 
type 1 diabetes development through the modulation of im-
mune function, especially through the expansion of Treg cells.
RETINOID METABOLISM AND INSULIN 
SENSITIVITY
There are several studies relating insulin resistance and the 
components of retinoid metabolism. The main link is the ef-
fect of RXR on glucose metabolism. Treatment of obese and 
diabetic mice with RXR pan-agonists improves glucose me-
tabolism [63]. However, it is unknown which RXR isoforms 
are involved in glucose metabolism and which organ is being 
targeted. Among the three RXR isoforms, RXRγ is preferen-
tially expressed in the skeletal muscle, and its expression is 
found to change according to nutritional status. Overexpres-
sion of RXRγ in mice showed higher glucose disposal than in 
control mice, and the skeletal muscle from mice overexpress-
ing RXRγ showed increased GLUT1 expression in an insulin-
independent manner [64]. Microarray data showed that RXRγ 
overexpression resulted in the increased expression of a diverse 
set of genes, including glucose metabolism genes. 
  Chronic feeding of a vitamin A-rich diet to adult male obese 
rats for 2 weeks decreased body weight gain and visceral WAT 
mass [65]. However, vitamin A had no impact on fasting plas-
ma glucose levels/insulin sensitivity. In another study from the 
same group, 50-day-old young male lean and obese rats were 
fed with either stock diet or vitamin A-enriched diet for 3 
months [66]. Compared with stock diet-fed obese rats, vita-
min A-enriched diet-fed obese rats had reduced body weight 
gain, visceral adiposity and improved insulin sensitivity as evi-
denced by decreased fasting plasma insulin and unaltered glu-
cose levels, which was due to higher phosphorylation of the 
soleus muscle insulin receptor. This is explained by decreased 
protein tyrosine phosphatase 1B levels in the soleus muscle. 
  In a recent review by Berry and Noy [67], they tried to ex-
plain the mechanism for the insulin resistance caused by the 
increased level of RBP in blood. They suggested that STRA6, a 
cell surface transporter that binds RBP and facilitates the move-
ment of retinol from the serum protein into cells, is not only a 
vitamin A transporter, but also functions as a surface signaling 
receptor. Binding of retinol-bound RBP (RBP-ROH) to STRA6 
induces the phosphorylation of a tyrosine residue in the recep-
tor C-terminus, thereby activating a JAK/STAT signaling cas-
cade. Consequently, in STRA6-expressing cells such as adipo-
cytes, RBP-ROH induces the expression of STAT target genes, 
including SOC3, which suppresses insulin signaling, and 
PPARγ. Whether RBP-ROH and STRA6 are involved in other 
biological functions remains to be clarified.
  From these results, there is no clear evidence linking reti-
noid metabolism with insulin sensitivity. More studies are 
needed to assess the role of retinoid metabolism in insulin 
sensitivity in various organs involved in insulin signaling.
RETINOID METABOLISM AND HEPATIC 
GLUCONEOGENESIS
Abnormal hepatic lipid and glucose metabolism significantly 
contribute to insulin resistance and metabolic derangements. 
The main key abnormalities are the altered expression of genes 
involved in lipid and glucose metabolism. 
  Glucokinase (GK) is an enzyme that phosphorylates glucose 
to glucose-6-phosphate, which is the first step of both glycogen 
synthesis and glycolysis. GK is exclusively expressed in hepa-
tocytes, and when the glucose level is high, GK serves as a cen-
tral metabolic switch to shift hepatic carbohydrate metabolism 
between fed and fast states [68]. In the study by Chen et al. [69], 174
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they made lipophyllic extract (LE) from rat liver and they 
found that LE synergized with insulin to induce Gck mRNA 
expression in primary hepatocytes. The active molecule in LE 
was identified as retinol and Rald by mass spectrometry. Reti-
noids synergize with insulin to induce Gck expression through 
the activation of both RAR and RXR. The in vivo study with 
Zucker lean rats fed with a vitamin A-deficient (VAD) diet 
demonstrated that hepatic GK activity and Gck mRNA levels 
were significantly lower than those of rats fed with a vitamin 
A-sufficient (VAS) diet. These results suggest that retinoids 
synergize with insulin to induce hepatic Gck expression.
  The authors from the above-mentioned study also reported 
on the synergistic effects of retinoids with insulin on sterol-
regulatory element binding protein 1-c (Srebp-1c) expression 
in primary hepatocytes [70]. Induced expression of Srebp-1c 
is followed by the elevation of fatty acid synthase (Fas), its tar-
get gene. Activation of RXR, but not RAR, is responsible for 
the induction of Srebp-1c expression. The RA-responsive ele-
ments in the Srebp-1c promoter were previously identified as 
two liver X receptor elements responsible for mediating insu-
lin action. These results indicate a role of vitamin A in the reg-
ulation of hepatic gene expression. 
RBP4 AND DIABETES
RBP4 is a member of the lipocalin family of proteins that trans-
port small hydrophobic molecules [71]. RBP4 transports reti-
nol from the liver to the peripheral tissues and plasma RBP4 
levels positively correlate with retinol levels. In a recent study, 
the ratio between RBP and retinol was measured in 233 hu-
mans divided into three groups depending on normal glucose 
tolerance (NGT), IGT and type 2 diabetes [32]. The RBP4-to-
retinol ratio was higher in type 2 diabetes compared with NGT 
subjects and was correlated positively with 2-hour postprandi-
al glucose levels, suggesting that RBP-to-retinol is more indic-
ative of type 2 diabetes than RBP itself. When the retinol:RBP4 
ratio was decreased by administration of atRA in diabetic ob/
ob mice, it improved insulin sensitivity and lowered body 
weight [72]. 
  The role of RBP4 in insulin resistance and obesity was dis-
covered by Barbara Kahn’s group in Beth Israel Deaconess 
Hospital, Boston, USA. They found that the mice with an adi-
pose-specific knockout of GLUT4 developed insulin resis-
tance and from DNA assays, they found that RBP4 expression 
was increased in adipose tissue of adipose GLUT4-/- mice and 
reduced in mice overexpressing adipose GLUT4 [73]. Serum 
RBP4 levels were increased and positively correlated with body 
mass index in obese non-diabetic and diabetic subjects [74]. 
Also, increased RBP4 levels were linked to increased visceral 
adipose tissue content. 
  However, the associations between RBP4 levels and mea-
sures of obesity or insulin resistance were not consistent. Sev-
eral studies found no correlation between RBP4 levels and 
obesity or the amount of adipose tissues [75,76]. Other studies 
failed to find a significant correlation between RBP4 levels and 
insulin resistance, IGT, type 2 diabetes or altered insulin secre-
tion. The suggested explanations for these discrepancies are 
the differences in the renal clearance of RBP4 caused by the 
different renal functions in the study subjects, the imbalance 
between RBP4 and retinol, the influence of the collection 
method, and the antibodies to measure RBP4 in immunoas-
says [77]. 
  The synthetic retinoid, fenretide (N-(4-hydroxyphenyl)ret-
inamide, FEN) reduces serum RBP4 levels in rodents and hu-
mans by disrupting the ternary complex of retinol-RBP4-trans-
thyretin and thereby promoting renal clearance of RBP4. When 
wild-type mice were fed a HFD with or without FEN, FEN 
treatment reduced HFD-induced adiposity and hyperlepti-
nemia. FEN improved insulin action on glucose uptake and 
glycogen levels in muscle, insulin-stimulated suppression of 
hepatic glucose production and suppression of serum FFA 
levels in HFD mice [78]. These effects are thought to be inde-
pendent of the RBP4-lowering effect, since similar effects were 
observed in RBP4-knockout mice. 
  In conclusion, RBP4 is an adipokine and a protein that 
transports retinol to the target tissues. Although there is still 
debate, RBP4 functions as a link between insulin sensitivity, 
obesity and type 2 diabetes. RBP4 might also be a clue to the 
relationship between retinoid metabolism and insulin sensi-
tivity and furthermore, diabetes. More specialized and target-
ed research has to be performed to uncover the basic role of 
RBP4 in metabolic diseases.
THE EFFECTS OF RETINOID THERAPY ON 
INSULIN SENSITIVITY AND LIPID PROFILES 
IN HUMANS
Although experimental evidence supports the role of retinoid 
treatment on glucose metabolism and adipogenesis in animals, 
inconsistent data are available from humans. Most human 175
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studies are based on post-treatment data obtained from pa-
tients treated with isotretinoin, a 13-cis retinoic acid, for acne, 
and etretinate, a synthetic retinoid, for psoriasis. Etretinate 
therapy for psoriasis was reported to be associated with a re-
duction in glucose levels in response to glucose load [79]. The 
treatment with acitretin, an aromatic all-trans retinoic acid, 
showed a mild, transient reduction of insulin sensitivity and 
high density lipoprotein cholesterol levels, and was not related 
to any modifications of adipocytokine levels [80].
  Isotretinoin is an effective drug for the treatment of acne, 
but elevated liver enzymes, dyslipidemia, insulin resistance, 
and type 2 diabetes during isotretinoin therapy have been re-
ported [81]. The mechanism underlying hypertriglyceridemia 
in retinoid-treatment is thought to involve impaired clearance 
of triglyceride-rich particles. In the study by Stoll et al. [82], 
whole body and adipose tissue insulin sensitivity in 15 healthy 
male volunteers before and after a 5-day administration of 
isotretinoin was assessed. Isotretinoin treatment increased 
plasma triglycerides, but did not change whole body insulin-
mediated glucose disposal and lipolysis. The authors conclud-
ed that impaired clearance of TG-rich particles due to isotreti-
noin treatment for 5 days does not impair insulin-mediated 
inhibition of lipolysis or glucose disposal. In a recent report by 
Ertugrul et al. [83], a total of 48 patients with acne vulgaris 
were treated with isotretinoin for 3 months. Although liver 
enzymes, total cholesterol, low density lipoprotein cholesterol 
and TG levels were elevated compared with baseline after 3 
months of treatment with isotretinoin, there was not a signifi-
cant change in fasting glucose, insulin, C-peptide levels or ho-
meostasis model assessment of insulin resistance (HOMA-IR) 
values before or after treatment, indicating that there is no ef-
fect of isotretinoin treatment on insulin sensitivity. In another 
study performed in 23 healthy acne patients, 3 months of treat-
ment with 13-cis retinoid acid resulted in increased HbA1c, 
TG, C-peptide and increased adiponectin levels, suggesting 
controversial effects of retinoid treatment on glucose metabo-
lism and adiponectin concentration [84]. 
  The results from the previously performed studies on the 
effects of retinoid treatment on insulin resistance and glucose 
metabolism did not show consistent results. Although they 
show some consistent trends, more studies are needed to ad-
dress their conclusive effects, since most of the studies were 
not initiated with glucose metabolism as the end point. There-
fore, randomized controlled studies with diabetes develop-
ment or glycemic progression as the end points should be de-
signed and performed to draw any conclusion regarding the 
effect of retinoid treatment on insulin sensitivity and metabo-
lism in humans.
RETINOID METABOLISM AND LIPID 
METABOLISM 
Vitamin A deficiency is known to favor fat deposition. Exten-
sive evidence has established that RAR and RXR participate in 
determining adipogenesis. For example, during adipogenesis, 
RXR expression patterns vary considerably, and the effects of 
atRA versus 9-cis-RA also vary depending on when cells are 
stimulated [85]. RAR plays an equal if not more dominant role 
in adipogenesis [86]. In RAR overexpressing cells, RA inhibits 
differentiation of 3T3-L1 cells during early stages of adipogen-
esis, but not when added 48 hours after differentiation has been 
initiated. Thus, although it is apparent that RA blocks adipo-
cyte differentiation in a certain stage of differentiation, the ef-
fect could vary according to the stage, including the levels of 
transcriptional factors.
  Rald has been primarily considered merely as a precursor 
for RA formation through irreversible oxidation by Raldh [87]. 
However, recent work suggests that Rald is present in fat tissue 
where it may exert effects independent of its conversion to RA 
[88]. Rald levels vary inversely with adiposity in mice fed a 
HFD, while levels of ADH and Raldh1 are also differentially 
regulated. Mice lacking Raldh1 are protected against diet-in-
duced obesity and diabetes. Consistent with the notion that 
Rald acts independently of its conversion to RA, administra-
tion of retinol, Rald, or RA to ob/ob mice had divergent effects 
on adiposity, with Rald limiting increases in visceral adiposity. 
Interestingly, in toxicology studies, citral, an inhibitor of Raldh 
activity, also induced weight loss [89]. Rald appears to inhibit 
RXR:PPARγ activation. 
  Another novel mechanism relating RA and fat metabolism 
is the recent observation that RA may have unique effects on 
lipid metabolism through differential effects on activating RARs 
versus PPARβ/δ [90]. RA is a proposed ligand for PPARβ/δ, a 
receptor involved in energy balance, lipid metabolism, and 
glucose homeostasis. PPARβ/δ activation increases lipid ca-
tabolism in skeletal muscle and adipose tissue, preventing the 
development of obesity [91]. In these studies, adipogenesis 
was accompanied by altered RA signaling in mature adipo-
cytes, with activation of RARs and PPARβ/δ, thus enhancing 
lipolysis and depleting lipid storage. In diet-induced obesity, 176
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RA treatment induced the expression of RAR and PPARβ/δ 
target genes involved in regulation of lipid homeostasis, fos-
tering weight loss. Despite these provocative results, more di-
rect studies are needed to understand how retinoids and reti-
noid-activated receptors modulate lipid metabolism and adi-
pogenesis and affect diabetes.
CONCLUSIONS
Retinoids might seem a little bit unfamiliar to the readers of a 
diabetes metabolism journal. However, there are many things 
to be uncovered regarding the role of retinoids on diabetes de-
velopment, insulin resistance, pancreatic dysfunction and lipid 
metabolism (Fig. 3). In general, two components in retinoic 
acid metabolism, RXR and atRA, are the main components 
that involve in glucose metabolism. Rexinoids are important 
in glucose and lipid metabolism, since they heterodimerize 
with PPARs, which are critical determinants in lipid and glu-
cose metabolism. Although rexinoids are known to function 
as insulin sensitizers, most of their effects are mediated through 
the dimerization with PPARγ. While RXR agonist influences 
primarily insulin sensitivity, retinoid acid, mostly atRA, affects 
insulin secretion and islet function through immunomodula-
tion. For the rexinoids to be considered as a novel therapeutic 
target for obesity or diabetes, higher specificity for certain RXR 
subtypes is mandatory. In addition, an interesting aspect of 
retinoids is the true function of Rald in metabolic diseases. It 
is not even clear yet whether Rald is a unique substrate that 
could function alone as a ligand to the nuclear receptors or just 
as an intermediate metabolite of retinoid metabolic pathways. 
There is a lot to learn about the effects and the function of Rald 
on metabolism. Further, there should be studies performed 
regarding the possible association between retinoids and the 
incretin system. If any effects of retinoid on the incretin system 
are found, retinoid could definitely be considered a new high-
lighted strategy that provides hope for a diabetes cure.
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Fig. 3. The effects of retinoids on glucose metabolism. RBP, retinol binding protein; ROH, retinol; STRA6; retinoic acid gene 6; 
RA, retinoic acid; RXR, retinoid X receptor; atRA, all-trans retinoic acid; 9cRA, 9-cis retinoic acid; Raldh3, retinaldehyde dehy-
drogenase 3.
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